April 16th 2024
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Durvalumab shows promise as perioperative addition for muscle-invasive urothelial carcinoma
September 5th 2023Adding perioperative durvalumab to standard care for patients with resectable muscle-invasive urothelial carcinoma demonstrated promising event-free and overall survival rates in a phase 2 trial.
Dr. Wang on personalized treatment selection in relapsed/refractory urothelial carcinoma
September 5th 2023In the setting of refractory urothelial carcinoma, Jue Wang, MD, says it is essential to thoroughly understand a patient's molecular profile, comorbidities, and residual side effects from prior lines of therapy.
Dr. Prasad shares the take-home message from the ATLAS study of UGN-102 in LG-IR NMIBC
August 18th 2023“I can tell you from a patient standpoint, I think we all agreed across the panel, there's going to be tremendous enthusiasm from patients about a nonsurgical option,” says Sandip M. Prasad, MD, MPhil.
UGN-102 linked with reduced risk of recurrence, progression, or death in LG-IR NMIBC
August 16th 2023“I think it's a very novel finding, and something completely new to urologic oncology, that a nonsurgical ablative option inside the body can actually make tumors go away,” says Sandip M. Prasad, MD, MPhil.
UGN-102 improves on current standard in low-grade intermediate-risk NMIBC
August 8th 2023The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.
Dr. Emamekhoo on how his institute is addressing the cancer drug shortage
July 19th 2023“One of the things we do is communicate with our teams and help them with some guidance about how to make decisions about which patients can potentially be treated with alternative approaches,” says Hamid Emamekhoo, MD.